RCS - CNS Pharmaceuticals - CNS to Host Virtual Analyst & Investor Day

MicrosoftAnnouncement

05/12/2024 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241205:nRSE9461Oa&default-theme=true

RNS Number : 9461O  CNS Pharmaceuticals, Inc  05 December 2024

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11,
2024

Live webcast discussion featuring internationally renowned Glioblastoma
Multiforme (GBM) Key Opinion Leaders

Company committed to addressing the most aggressive type of brain cancer with
an average survival of only 14 to 16 months after diagnosis and no cure

Register for the event here
(https://us02web.zoom.us/webinar/register/WN_prqhLQwvTZafU_EDkNqglA)

HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc.
(NASDAQ:CNSP) (https://pr.report/4qiy)  ("CNS" or the "Company"), a
biopharmaceutical company specializing in the development of novel treatments
for primary and metastatic cancers in the brain and central nervous system,
today announced it will host a Virtual Analyst & Investor Day
(https://pr.report/4qiz)  on Wednesday, December 11(th) from 11:30 AM - 1:00
PM ET.

For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD,
PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical
Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders:
Michael Weller, Prof. Dr. med. Director of Department, Department of
Neurology, Universitatsspital, Zurich, Switzerland; Samuel Goldlust, MD,
Board-certified and fellowship-trained neuro oncologist with Saint Luke's
Cancer Specialists; and Erin Dunbar, MD founding physician of the Brain Tumor
Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital.

As part of the event, the members of the CNS Pharmaceuticals management team
and participating KOLs will discuss GBM and provide an overview of Berubicin
and next steps for the clinical development program. Additionally,
participants will discuss the Company's second asset, TPI 287, and its
development and regulatory strategy moving forward.

A live video webcast  (https://pr.report/4qj0) of the event will be
available on the Events (https://pr.report/4qj1)  page of the Investors
(https://pr.report/4qj2)  section of the Company's website (cnspharma.com
(https://pr.report/4qj3) ). A webcast replay will be available two hours
following the live presentation and will be accessible for 90 days.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a
pipeline of anti-cancer drug candidates for the treatment of primary and
metastatic cancers of the brain and central nervous system. The Company's lead
drug candidate, Berubicin, is a novel anthracycline and the first
anthracycline to appear to cross the blood-brain barrier. Berubicin is
currently in development for the treatment of a number of serious brain and
CNS oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com (https://pr.report/4qj4)
, and connect with the Company on X (https://pr.report/4qj5) , Facebook
(https://pr.report/4qj6) , and LinkedIn (https://pr.report/4qj7) .

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities Litigation
Reform Act of 1995, which involve risks and uncertainties. These statements
relate to future events, future expectations, plans and prospects. Although
CNS believes the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been materially
different from the results expressed or implied by such forward-looking
statements. CNS has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions and involve
known and unknown risks, uncertainties and other factors, including market and
other conditions and those discussed under Item 1A. "Risk Factors" in CNS's
most recently filed Form 10-K filed with the Securities and Exchange
Commission ("SEC") and updated from time to time in its Form 10-Q filings and
in its other public filings with the SEC. Any forward-looking statements
contained in this press release speak only as of its date. CNS undertakes no
obligation to update any forward-looking statements contained in this press
release to reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events, except as required by law.

CONTACTS:

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908.824.0775

CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUVSSRSVUURRA